Measuring the burden of comorbidity for ischaemic heart disease and four common non-communicable diseases in Iran, 1990–2017: a modelling study based on global burden of diseases data. Issue 11 (17th November 2022)

• Record Type: Journal Article
• Authors: Mansourian, Marjan; Ghasemi, Khojasteh; Haghdoost, AliAkbar; Kopec, Jacek A; Sarrafzadegan, Nizal; Islam, Sheikh Mohammed Shariful
• Is Part Of: BMJ open. Volume 12:Issue 11(2022)
• Publication Date: 2022-11-17
• Subjects: epidemiology -- cardiology -- depression & mood disorders -- psychiatry -- diabetes & endocrinology; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2021-054441
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Objective: This modelling study aimed to estimate the comorbidity burden for four common non-communicable diseases with ischaemic heart diseases (IHD) in Iran during a period of 28 years. Design: Analysis of the burden of comorbidity with IHD based on data included prevalence rates and the disability weight (DW) average for calculating years lived with disability (YLDs) from the Iran population based on the Global Burden of Disease (GBD) study. Setting: Population-based available data in GBD 2017 study of Iran population. Participant: The source of data was the GBD 2017 Study. We evaluated IHD, major depressive disorder (MDD), diabetes mellitus (DM), ischaemic stroke (IS), and osteoarthritis (OA) age-standardised prevalence rates and their DW. Main outcome measures: A new formula that modified the GBD calculator was used to measure the comorbidity YLDs. In the new formula, some multipliers were considered, measuring the departure from independence. Result: The contribution of total comorbidity for each combination of IHD with DM, MDD, IS and OA was 2.5%, 2.0%, 1.6% and 2.9%, respectively. The highest YLD rates were observed for IHD_MDD, 16.5 in 1990 and 17.0 in 2017. This was followed by IHD_DM, from 11.5 to 16.9 per 100 000. The YLD rates for IHD_OA changed slightly (6.5–6.7) per 100 000, whereas there was a gradual reduction in the trends of IHD-IS, from 4.0–4.5 per 100 000. Conclusion: Of the four comorbidities studied, the highest burden was due to the coexistence of MDD with IHD. Our results highlight the importance of addressing the burden of comorbidities when studying the burden of IHD or any other non-communicable disease.